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Abstract: Gluten-related disorders are characterized by both intestinal and extraintestinal
manifestations. Previous studies have suggested an association between gluten-related disorder and
psychiatric comorbidities. The objective of our current review is to provide a comprehensive review
of this association in children and adults. A systematic literature search using MEDLINE, Embase and
PsycINFO from inception to 2018 using terms of ‘celiac disease’ or ‘gluten-sensitivity-related disorders’
combined with terms of ‘mental disorders’ was conducted. A total of 47 articles were included in our
review, of which 28 studies were conducted in adults, 11 studies in children and eight studies included
both children and adults. The majority of studies were conducted in celiac disease, two studies in
non-celiac gluten sensitivity and none in wheat allergy. Enough evidence is currently available
supporting the association of celiac disease with depression and, to a lesser extent, with eating
disorders. Further investigation is warranted to evaluate the association suggested with other
psychiatric disorders. In conclusion, routine surveillance of potential psychiatric manifestations in
children and adults with gluten-related disorders should be carried out by the attending physician.
Keywords: celiac disease; non-celiac gluten sensitivity; psychiatric disorders; depression;
anxiety disorders; eating disorders; ADHD; autism; psychosis
1. Introduction
Gluten-related disorders include three pathologies caused by the ingestion of gluten-containing
cereals grains, namely celiac disease (CD), non-celiac gluten sensitivity (NCGS) and wheat allergy
(WA) [1]. Although all of them are due to the toxicity of gluten proteins in the sensitive subject, their
respective pathogenetic mechanisms differ.
Celiac disease is a systemic autoimmune disease due to a permanent intolerance to gluten which
causes villous atrophy of the intestinal mucosa. It involves both innate and adaptive immune responses
that appear in genetically predisposed subjects exposed to gluten and, unlike food allergies, it is not
mediated by an immediate hypersensitivity reaction. It is a polygenic multifactorial disorder whose
development depends on the genetic constitution of the subject, on his/her exposure to gluten intake,
and on different environmental factors [2,3]. To date, the only effective treatment for the disease is to
observe a life-long strict gluten-free diet although other therapeutic approaches are being explored [4].
In relation to the genetic background of the disease, two HLA class II genes, the HLA-DQ2 and
the HLA-DQ8 heterodimers are present in almost all CD patients and their simultaneous absence
in a subject usually rules out a diagnosis of CD. However, these genes are also common in the
general population and the implication of other non-HLA genes is being investigated by genome
wide association studies [5]. Environmental factors that facilitate or, conversely, protect against the
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development of CD are defectively known although they are considered important given that the
genetic background is not enough to explain the increasing incidence and prevalence of CD [2].
Infant feeding practices such as the timing of the first gluten introduction in the diet and the presumed
protective role of maternal breastfeeding that were once considered important, have been recently
shown to be irrelevant in relation to the development of CD [6]. In contrast, gastrointestinal infections
and antibiotics use during the first year of life seem to be associated with a higher risk of developing
CD [7]; these latter factors could be related with the composition of gut microbiota that seems to be
different between children with and without CD [8].
As both the two most relevant genes associated with the development of CD as well as the
consumption gluten-containing foods are fairly prevalent in most of the world, it is not surprising
that there is high worldwide prevalence of CD [9]. The global worldwide prevalence of CD has been
shown to be higher when diagnosed only by serological tests, i.e., anti-tissue transglutaminase and/or
antiendomysial antibodies (1.4%, 95% confidence interval [CI] 1.1–1.7%) than when diagnosed with
intestinal biopsy (0.7%, 95% CI 0.5–0.9%) [10]. Some striking differences have been found among
different geographic areas; differences that are probably due to different genetic haplotypes, different
patterns of gluten-containing foods intake, and environmental differences. CD has been found to be
more frequent in females than in males and in children than in adults [10]. A fact worthy of mention
is that the CD prevalence has been increasing during the last decades [2,10]. This increase must be
partially attributed to an augmented awareness about the disease and more accurate diagnosis, but
environmental factors are also responsible for being the most relevant the increase to gluten exposure
in countries where nutrition traditionally relied on the intake of gluten-free grains such as rice or
corn [3].
The clinical manifestations of CD can be both gastrointestinal and extraintestinal. Gastrointestinal
symptoms include diarrhea, steatorrhea, abdominal pain, abdominal bloating, vomiting and failure to
thrive due to the malabsorption process. This kind of symptomatology is more frequent in children
and was formerly called “typical CD”, a term that has currently been replaced by “classic” CD [3].
Among the extraintestinal manifestations, some of them such as ferropenic anemia, osteopenia
and osteoporosis, short stature or dental enamel hypoplasia, are a consequence of the intestinal
malabsorption process. Others, however, seem to be due to the noxious effect of gluten in the affected
organs; dermatitis herpetiformis, gluten ataxia, gluten encephalopathy, epileptic seizures or elevation
of liver enzymes are examples of the latter. Extraintestinal symptoms, which are more frequently
found among adolescents and adults, were initially known as “atypical” CD, a term that has now been
replaced by “symptomatic” CD [3].
CD is frequently comorbid with mainly other autoimmune disorders, although non-exclusively,
type1 diabetes, Graves’ disease and inflammatory bowel diseases [11,12]. It has also been found to be
associated with a higher risk of non-Hodgkin lymphoma [13,14] and with Down [15,16] and Turner
syndromes [15,17].
Unlike CD, NCGS has not been shown to be associated with underlying autoimmune mechanisms.
Similar to patients with CD, subjects that experience NCGS may, after gluten intake, suffer a wide
variety of intestinal and/or extraintestinal symptoms that improve after following a gluten-free diet.
Contrarily to CD, the presence of anti-tissue transglutaminase and/or antiendomysial antibodies is
always negative, the HLA-DQ2/HLA-DQ8 combination in these patients is only slightly more frequent
than in the general population, and there is no atrophy of the small intestine mucosa although a rise in
intraepithelial intestinal lymphocytes has been observed [18]. Its prevalence is not yet well-known
although it does not seem to be an uncommon disease [19]. The pathogenetic mechanisms of NCGS
are, at present, poorly understood. Patients with NCGS benefit from a gluten-free diet but they have
been also shown to improve following a low FODMAPs (fermentable, oligo-, di-, monosaccharides
and polyols) diet, a fact that suggests that other constituents of grains may be responsible for the
symptoms of the disease [20].
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Wheat allergy is an IgE-mediated reaction to the proteins contained in wheat and in particular,
although not exclusively, the omega-5-gliadin. WA can be developed by inhalation of wheat flour,
the so-called baker’s asthma and baker’s rhinitis which are considered occupational diseases, or by
wheat ingestion [21]. The latter case, which is the most frequent, may cause urticaria, angioedema
and/or gastrointestinal symptoms such as nausea, vomiting, abdominal bloating, abdominal pain and
diarrhea; in the most severe cases it can induce systemic anaphylaxis [18]. WA is especially frequent in
children, being less commonly seen in adolescents and adults. The treatment is based on the avoidance
of wheat-containing foods, being less restrictive compared to gluten-free diet in CD, as it does not
require the restriction of rye and barley-containing foods [22].
Psychiatric disturbances have frequently been reported in patients with CD. Several narrative
reviews of the literature undertaken in the last five years indicate that CD could be associated with a
wide spectrum of psychiatric disorders, including anxiety disorders, dysthymia, major depression,
bipolar disorders, schizophrenia, eating disorders, autism spectrum disorders, and attention-deficit
hyperactive disorders [23–27]. However, these otherwise important reviews have several limitations.
Several of them were focused on specific psychiatric disorders such as anxiety and depression [24],
mood disorders and schizophrenia [25], or severe psychiatric disorders [27]. Some others, according to
their objectives comprised the whole spectrum of psychiatric disorders, but they do not specify their
search strategies and/or the biomedical literature database used for the review [23,26]. Finally, when
specified, literature searches were almost restricted to PubMed, thus providing a limited review of the
literature on this topic. Moreover, none of the previous have evaluated the association of psychiatric
disorders in children and adults with gluten-related disorders separately. The aim of this manuscript
is presenting a comprehensive review of the literature on the potential association of gluten-related
disorders with the whole spectrum of psychiatric disorders using the most common literature databases
for this kind of evaluation (namely, Medline, EMBASE and PyscINFO).
2. Methodology
2.1. Search Strategy
We searched the medical literature for published studies indexed in the Medline (1966 to January
2018), EMBASE (1947 to January 2018), and PsycINFO (1967 to January 2018). The search strategy
included terms of ‘celiac disease’ or ‘gluten-sensitivity related disorders’ combined with terms of
‘mental disorders’ as described in Supplementary Table S1. No limits or restrictions were applied.
Retrieved references were pooled and managed using EndNote X8 (Clarivate Analytics, Philadelphia,
PA, USA).
2.2. Inclusion Criteria
We included studies that investigated the prevalence, incidence or the likelihood of presenting
mental or psychiatric disorders in patients with CD or gluten-sensitivity related disorders. For that
purpose, comparative observational or interventional studies, including meta-analysis, assessing the
aforementioned objectives as part of their primary or secondary objectives were included. Only studies
published in English, Spanish, French, Portuguese, or Italian were included. Case-reports, case-series,
abstracts and editorials were excluded. The relationship between CD and psychiatric disorders
may be bidirectional. Our purpose was to assess the comorbidity between gluten-related disorders
and psychiatric manifestations; thus, those studies assessing the prevalence, incidence or likelihood
of presenting CD or gluten-related disorders in patients with diagnosed psychiatric disorders
were excluded.
Study eligibility was independently evaluated by the three investigators (MS, EPC, FRV).
Discrepancies in the evaluation were resolved by consensus among study investigators.
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2.3. Data Extraction
Standardized data collection forms were used to extract data that included: (1) name of the first
author; (2) year of publication; (3) country where the study was conducted; (4) study objective(s);
(5) study design; (6) assessment tools used in psychiatric comorbidities evaluation; (7) Disease
diagnostic criteria; (8) sample size and demographic characteristics; and (9) summary of outcomes.
Data extraction was independently completed by two investigators (MS and FRV). Discrepancies in
data extraction were solved by consensus.
3. Results
3.1. Study Selection
Our systematic search strategy identified 1375 potentially relevant articles (730 articles from
EMBASE, 453 articles from MEDLINE and 192 articles from PsycINFO). After removing 461 duplicate
articles, 914 articles underwent title and abstract screening. Seven hundred and eighty-eight articles
were excluded as they were case-reports, editorials, animal studies, basic science studies, did not
include comparator group, or were published in a language other than those specified in the inclusion
criteria, leaving 126 articles for a full-text screening. Two studies were excluded because we were
unable to obtain their full text [28,29]. A total of 77 were excluded following full-text review because
they were either published in abstract form, did not meet the specific objectives set for our current
review or did not report outcomes of interest, leaving a total of 47 articles that were included in our
review, of which 28 studies were conducted in the adult population, 11 studies were conducted in the
pediatric population and eight studies included both adults and children. Mixed studies (including
children and adults, n = 8) were classified under the corresponding population group with a larger
sample size (pediatrics (n = 4), adults (n = 4)) (Figure 1).
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3.2. Studies Conducted in Children with CD
We found 15 studies that evaluated psychiatric disorders in children or young adults with CD,
11 of which were conducted in clinical-based settings and four were conducted in community-based
settings (Table 1). Studies were published between 1997 and 2018 [30–44]. Most studies (n = 12) were
cross-sectional, although one of them included a subsequent longitudinal phase [41]. Three studies
used a population-based cohort design and were conducted in Sweden using the same data source for
patients with CD [31,34,44]. Finally, one study used a cohort design [38]. With the exception of this
later study which was conducted in several countries [38], the remaining studies were conducted in
European countries or Turkey.
According to a population-based cohort study, children with CD have a 70% increased likelihood
of presenting a psychiatric disorder with intellectual disability being the most likely disorder (HR
1.7, 95% CI 1.4 to 2.1) [44]. A summary of results of studies evaluating the association between CD
and the occurrence or presence of psychiatric disorders is presented in Table 2. Regarding specific
conditions, cohort studies have shown that CD is associated with an increased likelihood of occurrence
of depression (HR = 1.8, 95% CI 1.6 to 2.2) [34] or mood disorders (HR 1.2, 95% CI 1.0–1.4) [44],
although this latter result did not reach statistical significance. In contrast, most cross-sectional studies
have found that the point prevalence of depression or the severity of depressive symptoms did not
differ in children with CD as compared with controls [33,35–37]. Pynnonen et al. [32], using a cross
sectional study, found no differences between patients with CD and controls in the point prevalence of
major depressive disorder, but the lifetime prevalence of major depressive disorder was significantly
increased in patients with CD (31% vs. 7%; OR = 6.06, 95% CI 1.18–31.23). Although a population-based
study found an increased likelihood of occurrence of anxiety disorder in patients with CD as compared
with controls (HR 1.2, 95% CI 1.0 to 1.4, p <0.05) [44], cross-sectional studies have not shown differences
between patients with CD and controls in the prevalence or severity of symptom of anxiety [32,35,36].
In children, no association has been found between CD and the occurrence of bipolar disorder [34].
The association of CD with psychotic disorders in children has been scarcely investigated, showing
no association with the occurrence of schizophrenia [31] or psychotic disorder [44]; an association
has been reported between CD and non-schizophrenic non-affective psychosis (HR 1.61, 95% CI
1.19–2.20) [31].
A population-based study found a significant association between CD and the occurrence of an
eating disorder (HR 1.4, 95% CI 1.1 to 1.8) [44], and the presence of the disorder seems to have a negative
impact on some dimensions of quality of life (namely, ill-being and joy-in-life) [39]. A population-based
cohort found an excess likelihood of occurrence of an autism spectrum disorder in patients with CD as
compared to controls [44]; however, a cross-sectional study did not find an association between both
disorders [30]. A slight, but significant, increase in the likelihood of occurrence of attention deficit and
hyperactive disorder (ADHD) in patients with CD has been reported [44].
Several factors have been suggested to contribute to depressive symptomatology in the pediatric
population including the presence of parental depressive disorders, low parental educational level,
divorce of the parents, presence of functional comorbid conditions and female gender [32,33,43].
Older age, higher body mass index and history of dietary restrictions were linked to higher risk of
eating disorders [39,40].
3.3. Studies Conducted in Adults with CD
We found 32 studies that evaluated psychiatric comorbidities in adult patients with CD or NCGS,
18 of which were conducted in clinical-based settings and nine were conducted in community-based
settings (Table 3). Studies were published between 1982 and 2018 [45–76]. More than half of these
studies were of cross-sectional design [45,48,51,53–57,59,60,63,67,68,71,72,74–76] and four of them
were representative of the general population [47,70,73,76].
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Table 1. Objectives and design of studies evaluating the association between gluten-related disorders and psychiatric disorders in children and young adults.
Author (Year) Country Primary Objective Design ‡ Study Setting
Psychiatric Comorbidity
Assessment
Celiac Disease
Diagnostic Criteria
Autism spectrum disorders
Pavone (1997) [30] Italy To evaluate behavioral problems and autistic features in childrenwith CD Cross-sectional Clinical DSM-III-R Biopsy
Schizophrenia Spectrum
Ludvigsson (2007) * [31] Sweden To determine the risk of non-affective psychosis in patients withCD in a national general population cohort
Population-based
cohort Community ICD ICD
Bipolar, depressive and anxiety disorders
Pynnonen (2004) [32] Finland To compare the prevalence of current and lifetime mentaldisorders in adolescents with CD and controls Cross-sectional Clinical
K-SADS-PL
Youth Self-Report
BDI and BAI
HDRS and HARS
Biopsy
Accomando (2005) * [33] Italy To investigate the relationship between CD and depression Cross-sectional Clinical CDQ (adults)CDS (children) NR
Ludvigsson (2007) * [34] Sweden To investigate the risk of subsequent depression and bipolar inpatients with CD
Population-based
cohort Community ICD NR
Fidan (2013) [35] Turkey
To investigate the depression and anxiety levels of children and
adolescents with celiac disease and the impact of these on
quality of life
Cross-sectional Clinical CDISTAIC NR
Esenyel (2014) [36] Turkey To explore the diet compliance and depression and anxietylevels of pediatric celiac children and their families after a GFD Cross-sectional Clinical
CDI
SCARED ESPGHAN criteria
Simsek (2015) [37] Turkey To evaluate depressive symptoms at time of CD diagnosis and 6months following GFD initiation
Phase 1:
Cross-sectional
Phase 2:
Case-series
Clinical CDIHRQOL (Kid-KINDL) Biopsy
Smith (2017) [38] USA, Finland, Germany,and Sweden
To assess mother’s report of psychological functioning in
children with CDA Cohort Community CBCL
Serology and
optional biopsy
Feeding and eating disorders
Wagner (2015) [39] Austria To assess the determinants of eating disorders in femaleadolescents with CD Cross-sectional Clinical
EDI-2
EDE
DSM-IV for subclinical
eating disorders
CDI (total score ≥ 18)
Both
Babio (2018) * [40] Spain To assess the risk of eating disorders in individuals between 10and 23 years old diagnosed with CD Cross-sectional Clinical
CEAT
EAT-26
SCFF
BITE
BSQ
Both
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Table 1. Cont.
Author (Year) Country Primary Objective Design ‡ Study Setting
Psychiatric Comorbidity
Assessment
Celiac Disease
Diagnostic Criteria
Overall psychological status
Terrone (2013) [41] Italy To screen for neurological and behavioral disorders in childrenwith CD
Phase 1:
cross-sectional
Phase 2: cohort
Clinical PSC (total score ≥ 28) ESPGHAN criteria
Various psychiatric conditions
Ruggieri (2008) [42] Italy To determine the prevalence of neurologic symptoms in childrenwith gluten sensitivity enteropathy Cross-sectional Clinical NR Both
Mazzone (2011) [43] Italy To identify psychological features in children with CD followingstrict GFD Cross-sectional Clinical
MASC
CBCL
CDI
DSM-IV-TR criteria to
assess autistic disorders
ESPGHAN criteria
Butwicka (2017) [44] Sweden
To examine the risk of psychiatric disorders in children with a
biopsy-verified diagnosis of CD and to examine the prevalence
of psychiatric disorders before CD is diagnosed in children
Population-based
cohort Community ICD Biopsy
* Included patients of all age groups (pediatrics and adults); ‡ The design was determined by the authors of the current review which might not coincide with the design described in
the original studies; for studies including multiple methodologies, the design that achieved the objectives of interest was selected; BAI: Beck Anxiety Inventory; BDI: Beck Depression
Inventory; BITE: Bulimia Investigatory Test Edinburgh; BSQ: Body Shape Questionnaire; CBCL: Achenbach Child Behavior Checklist; CD: celiac disease; CDA: celiac disease autoimmunity;
CDI: Child Depression Inventory; CDQ: Clinical Depression Questionnaire; CDS: Children Depression Scale; CEAT: Children Eating Attitudes Test; DSM: Diagnostic and Statistical Manual
of Mental Disorders; EAT: Eating Attitudes Test; EDE: Eating Disorder Examination; EDI: Eating Disorder Inventory; ESPGHAN: The European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition; GFD: gluten-free diet; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating Scale; HRQOL: Health-Related Quality of Life; ICD:
International Classification of Disease; KINDL: German questionnaire for measuring quality of life in children and adolescents; K-SADS-PL: Schedule for Affective Disorders and
Schizophrenia for school-Age Children-Present and Lifetime version; MASC: Multidimensional Anxiety Scale for Children; NR: not reported; PSC: Pediatric Symptom Checklist; SCARED:
Childhood Anxiety Disorders Screening Measure; SCFF: Sick Control Fat Food; STAIC: State-Trait Anxiety Inventory for Children.
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Table 2. Summary of outcomes evaluating the association between gluten-related disorders and psychiatric disorders in children and young adults.
Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and Other Relevant Information
Autism spectrum disorders
Pavone (1997) [30] Cross-sectional
CD, n = 120 (mean age 9.6 years, 48% females)
Recently-diagnosed CD, n = 27
CD on strict GFD, n = 70
GFD non-adherent CD, n = 23
Controls, n = 20 (mean age 9.6 years, 48% females)
- Autism diagnosis: none of the recently-diagnosed CD
- Language delay: Two subjects in GFD-compliant, one subject in the
non-adherent group
- Differences were not statistically significant compared to controls
NR
Schizophrenia Spectrum
Ludvigsson (2007)
[31]
Population-based
cohort study
CD, n = 14,003 (age at diagnosis, 0–15 years 66% &
≥16 years 34%; 59% females)
Controls, n = 68,125 (matched age and gender)
- Likelihood of psychosis in CD vs. controls using a Cox regression
model stratified for gender, age, year of study entry and county:
Any non-affective psychosis (schizophrenia and other psychoses) HR
= 1.55 (95% CI: 1.16–2.06)
Non-schizophrenic non-affective psychosis HR = 1.61 (95% CI:
1.19–2.20)
Schizophrenia HR = 1.43 (95% CI: 0.77–2.67)
NR
Bipolar, depressive and anxiety disorders
Pynnonen (2004) [32] Cross-sectional CD, n = 29 (mean age 14.2 years, 55% females)Controls, n = 29 (mean age 14.4 years, 55% females)
- Lifetime prevalence of major depression disorder (CD vs. controls):
31% vs. 7%, p <0.05. OR = 6.06 (95% CI: 1.18–31.23).
- Disruptive behavior disorders (CD vs. controls):
28% vs. 3%, p <0.05. OR = 10.67 (95% CI: 1.24–92).
- Lifetime prevalence of anxiety disorders (CD vs. controls):
21% vs. 24%, p = NS
- Differences in the prevalence of current depressive, anxiety, or
disruptive behavior disorders between the two groups were
non-significant
- History of parental depressive disorder was more
common in CD patients with depressive
symptomatology compared to CD without
depressive symptomatology
- Parental educational level, divorce of parents,
poor weight or height gain, and somatic symptoms
were not associated with mental disorders
Accomando (2005)
[33] Cross-sectional
CD, n = 42 (17 adults and 25 children)
HC, n = 42
Prevalence of depression (CD vs. HC):
26.2% vs. 30.9%, p = NS
- Females predominated in CD patients with
depression (not reaching statistical significance)
- Depression was more common in CD with
functional comorbid conditions (specific
conditions not specified)
Ludvigsson (2007)
[34]
Population-based
cohort study
CD, n = 13,776 (median age at diagnosis 2 years,
58.6% females)
Controls, n = 66,815 (median age at diagnosis 2 years,
58.7% females)
- CD was associated with an increased risk of subsequent depression
(HR = 1.8, 95% CI: 1.6–2.2)
- No significant association between CD and bipolar disorder was
reported (HR = 1.1, 95% CI: 0.7–1.7)
- Socioeconomic index didn’t have any
confounding effect on the later schizophrenia
diagnosis in CD
Fidan (2013) [35] Cross-sectional CD, n =30 (mean age 12.4 ± 3.1 years, 57% females).HC, n = 30 (mean age NR, 57% females)
- CD vs. HC:
CDI: 10.8 ± 7.4 vs. 8.8 ± 6.8, p=0.28
STAIC-State Anxiety: 34.6 ± 6.1 vs. 32.8 + 7.2, p = 0.30
STAIC-Trait Anxiety: 33.7 ± 6.5 vs. 33 ± 6.3, p =0.64
- Data on the impact of depression and anxiety on
HRQOL NR
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Table 2. Cont.
Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and Other Relevant Information
Esenyel (2014) [36] Cross-sectional CD, n = 30 (mean age 11.9 ± 2 years, 70% females)HC, n =20 (mean age 12 ± 2 years, 55% females)
- CD vs. HC:
CDI points: 8.73 ± 5.51 vs. 8.3 ± 4.02, p = 0.921
SCARED points: 24.5 ± 14.41 vs. 17.85 ± 9.12, p = 0.120
- There were no differences in depression and anxiety scores between
patients with CD compliant or non-compliant with a GFD
NR
Simsek (2015) [37]
Phase 1:
Cross-sectional
Phase 2: Case-series
CD, n = 25 (mean age 11.8 years, 72% females)
Controls, n = 25 (mean age 12.2 years, 64%)
- At the time of diagnosis (CD vs. controls):
CDI scores: 9 vs. 6, p = NS
- 6 months following GFD initiation:
CDI scores in CD: 9 before diet vs. 9.5 after diet, p = NS
- Total scores of HRQOL were significantly lower
in CD patients (p <0.05)
Smith (2017) [38] Cohort
Aware-CDA, n = 440 (58% females)
Unware-CDA, n = 66 (50% females)
No CDA, n = 3651 (NR)
- At 3.5 years of age, unaware-CDA mothers reported more
anxious/depressed symptoms, aggressive behavior, and
externalizing composite score compared to aware-CDA group
(p <0.05) or without CDA (p <0.05)
- At 3.5 years of age, Aware-CDA mothers reported significantly
fewer problems on the anxious/depressed subscale compared to No
CDA group (p = 0.03)
- At 4.5 years, there were no significant differences
NR
Feeding and eating disorders
Wagner (2015) [39] Cross-sectional
CD, n = 206 (mean age NR)
CD with ED, n = 32 (mean age 16.4 yeas)
CD without ED, n = 174 (mean age 14.5 years)
Controls, n = 53 (mean age 14.7 years)
- Lifetime prevalence of EDs:
5.3% of girls with CD: anorexia nervosa (n = 1), bulimia nervosa
(n = 4), and EDs not otherwise specified (n = 6); 3.9% suffered from
current ED
- Criteria for lifetime subclinical EDs:
21 girls (10.2%) with CD
- Higher BMI and self-directedness were predictors of greater risk
of ED
- Higher ill-being and lower joy in life were reported by patients with
CD with ED compared with patients without EDs, even when
controlling for age and depression levels
- No differences between patients (with CD) with
and without EDs in coping strategies were found
- Higher BMI and lower self-directedness were
linked to higher risk of ED in CD
Babio (2018) [40] Cross-sectional CD, n = 98 (mean age 15 years, 60% females)Controls, n = 98 (mean age 15 years, 60% females)
- No significant differences in the median scores of the screening
tools for EDs between CD and HC
- CD vs. HC: β coefficient = 2.15 (1.04); p = 0.04 in a multiple linear
regression model for EAT after adjusting for several factors
- Only significant results for one out of the 4
models (one for each screening test)
- Age > 13 years old was positively associated with
an increase in the score on the EAT
Overall psychological status
Terrone (2013) [41]
Phase 1:
cross-sectional
Phase 2: cohort
CD, n = 139 (mean age 10 years, 64.7% females):
Group A (n =40): newly diagnosed CD
Group B (n = 54): CD in remission on GFD > 1 year
Group C (n = 45): potential CD
- Comparison of mean PSC scores using ANOVA:
Group A, 14.8 ± 4.2 (one pathological score) vs. Group B, 12.3 ± 6.4
(one pathological score) vs. Group C, 7.6 ± 6 (p <0.0001)
NR
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Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and Other Relevant Information
Various psychiatric conditions
Ruggieri (2008) [42] Cross-sectional GS, n = 835 (demographic characteristics NR)Controls, n = 300 (demographic characteristics NR)
- 3 out of 835 children had bipolar disorders
- None of the controls had psychiatric disorders NR
Mazzone (2011) [43] Cross-sectional CD, n = 100 (mean age 10.4 years, 65% females)HC, n = 100 (mean age 11.5 years, 58% females)
- MASC scores:
CD children showed significantly higher scores (50 ± 8.3 vs.
42.9 ± 6.6, p <0.01)
- CDI scores:
CD children showed significantly higher scores (8.1 ± 5.7 vs.
5.6 ± 3.4, p <0.01)
- No significant differences were found in CBCL analysis
- Two children in the CD group were classified within the spectrum
of autistic disorders
- CD males showed significantly higher scores for
total CBCL
- CD females showed an increased rate of anxiety
and depression symptoms, as
indicated by significantly higher MASC and
CDI scores
Butwicka (2017) [44] Population-basedcohort study
CD, n = 10,903 (median age 3 years, 62% females)
Controls, n = 1,042,072 (age NR but matched,
61% females)
- HRs from a Multivariate Cox regression adjusted for
maternal/paternal age at child’s birth, maternal/paternal country of
birth, level of education of higher-educated parent, gestational age,
birth weight, birth cohort, Apgar score, and history of psychiatric
disorders before recruitment:
Any psychiatric disorder 1.4 (95% CI: 1.3–1.4)
Psychotic disorders 1.9 (95% CI: 1.0–3.5)
Mood disorders 1.2 (95% CI: 1.0–1.4)
Anxiety disorders 1.2 (95% CI: 1.0–1.4)
EDs 1.4 (95% CI: 1.1–1.8)
Substance misuse 1.0 (95% CI: 0.9–1.3)
Behavioral disorders 1.4 (95% CI: 1.2–1.6)
ADHD 1.2 (95% CI: 1.0–1.4)
Autism spectrum disorder 1.3 (95% CI: 1.1–1.7)
Intellectual disability 1.7 (95% CI: 1.4–2.1)
NR
ADHD: Attention-Deficit Hyperactivity Disorder; ANOVA: analysis of variance; BMI: body mass index; CBCL: Achenbach Child Behavior Checklist; CD: celiac disease; CDA: celiac
disease autoimmunity; CDI: Child Depression Inventory; CI: confidence interval; EAT: Eating Attitudes Test; ED: eating disorder; GFD: gluten free diet; GS: gluten sensitivity; HC: healthy
controls; HR: hazard ratio; HRQOL: Health-Related Quality of Life; MASC: Multidimensional Anxiety Scale for Children; NR: not reported; NS: not significant; OR: odd ratio; PSC:
Pediatric Symptom Checklist; SCARED: Childhood Anxiety Disorders Screening Measure; STAIC: State-Trait Anxiety Inventory for Children; vs: versus.
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Table 3. Objectives and design of studies evaluating the association between gluten-related disorders and psychiatric disorders in adults.
Author (Year) Country Primary Objective Design ‡ Study Setting Psychiatric Comorbidity Assessment Celiac Disease Diagnostic Criteria
Attention-Deficit/Hyperactivity Disorder
Zelnik (2004) * [45] Israel To evaluate neurologic disorders includingADHD in CD Cross-sectional Clinical DSM criteria for ADHD Both
Autism spectrum disorders
Ludvigsson (2013) *
[46] Sweden
To examine the association between autistic
spectrum disorder and CD Cohort study Community ICD
Group 1: villous atrophy, Marsh stage 3
Group 2: villous atrophy, Marsh stages 1–2
Group 3: normal mucosa and positive
serologic findings
Schizophrenia Spectrum
West (2006) [47] UK
To compare the risk of schizophrenia in patients
with CD, ulcerative colitis, Crohn’s disease with
the general population
Population-based
cross-sectional Community NR NR
Eaton (2006) [48] Denmark To estimate the association of schizophrenia withautoimmune disorders Cross-sectional Community ICD ICD
Benros (2011) [49] Denmark To investigate whether autoimmune diseases areassociated with increased risk of schizophrenia
Population-based
retrospective cohort Community ICD NR
Wijarnpreecha (2018)
[50] USA
To evaluate the risk of developing schizophrenia
among patients with CD Meta-analysis NA NR NR
Bipolar, depressive or anxiety disorders
Hallert (1982) [51]
Hallert (1983) [52] Sweden
To compare the prevalence of psychiatric illness
among patients with CD vs. controls and to
assess the effects of gluten withdrawal and
vitamin B6 supplement on depressive symptoms
Phase 1:
cross-sectional
Phase 2: case-series
Clinical MMPI Both (serological and biopsy) combinedwith morphological improvement with GFD
Addolorato (1996)
[53] Italy
To conduct psychometric evaluation in patients
with CD or IBD compared to healthy controls Cross-sectional Clinical
STAI
IDSQ Both
Ciacci (1998) [54] Italy To explore the relevance of depressive symptomsin a large series of adult celiacs Cross-sectional Clinical SRDS Both
Addolorato (2001)
[55] Italy
To evaluate state and trait anxiety and depression
in adult CD patients before and after 1 year
of GFD
Phase 1:
Cross-sectional
Phase 2: Case-series
Clinical STAISRDS Both
Cicarelli (2003) [56] Italy
To evaluate the prevalence of headache, mood
disorders, epilepsy, ataxia and peripheral
neuropathy in adult celiac patients
Cross-sectional Clinical DSM-IV Both
Carta (2002) [57]
Carta (2003) [58] Italy
To evaluate the association between celiac disease
and specific anxiety and depressive disorders Cross-sectional Clinical CIDI-DSM-IV Both
Addolorato (2008)
[59] Italy To evaluate social phobia in CD patients Cross-sectional Clinical
LSAS total > 30
SRDS > 49 Both
Nutrients 2018, 10, 875 12 of 29
Table 3. Cont.
Author (Year) Country Primary Objective Design ‡ Study Setting Psychiatric Comorbidity Assessment Celiac Disease Diagnostic Criteria
Garud (2009) [60] US
To determine the prevalence of psychiatric and
autoimmune disorders in patients with CD in the
US compared with control groups
Cross-sectional Community Clinical charts Biopsy
Smith (2012) [61] Denmark To investigate whether CD is reliably linked withanxiety and/or depression Meta-analysis NA NA NA
Peters (2014) [62] Australia To investigate the effect of gluten on mental stateamong patients with NCGS
Randomized,
double-blind,
cross-over trial
Clinical STPI Challenging with varying amounts of gluten
Carta (2015) [63] Italy To measure the association between CD andaffective disorders Cross-sectional Clinical DSM-IV NR
Di Sabatino (2015)
[64] Italy
To assess the effects of gluten administration on
intestinal and extraintestinal symptoms in
subjects with NCGS
Randomized,
double-blind,
placebo-controlled
cross-over trial
Clinical
Extraintestinal symptoms, including
depression, were self-reported by patients
as absent or present
Self-reported persistence of relevant
intestinal and extraintestinal symptoms at
low gluten doses
Tortora (2013) [65] Italy To evaluate the prevalence of post-partumdepression in CD Cross-sectional Clinical EPDS (Total score > 10 possible PPD) Both
Sainsbury (2018) [66] UK
To synthesize the evidence on the relationship
between depression and degree of adherence to
GFD in patients with CD
Meta-analysis NA NA NA
Feeding and eating disorders
Passananti (2013) [67] Italy To investigate the prevalence of eating disordersin patients with celiac disease Cross-sectional Clinical
Structured psychological assessment using:
BES (Total score ≥ 17)
EAT-26 (Total score ≥ 20)
EDI-2
M-SDS (Total score > 44)
SCL-90
Both
Satherley (2016) [68] UnitedKingdom
To examine the prevalence of eating disorders in
women with CD Cross-sectional Clinical
EAT-26 (Total score > 20)
BES (Moderate bingeing, score > 17; severe
bingeing, score > 27)
DASS-21
Self-reported a biopsy-confirmed diagnosis
Mårild (2017) * [69] Sweden To determine whether women with CD are atincreased risk of diagnosis of anorexia nervosa
Register-based cohort
study Community ICD
Group 1: villous atrophy, Marsh stage 3
Group 2: villous atrophy, Marsh stages 1–2
Group 3: normal mucosa and positive
serologic findings
Sleep-Wake disorders
Marild (2015) * [70] Sweden
To estimate the risk of repeated use of hypnotics
among individuals with CD as a proxy measure
for poor sleep
Population-based
cohort study Community
Prescribed Drug Register in Sweden—Use
of hypnotics Biopsy
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Table 3. Cont.
Author (Year) Country Primary Objective Design ‡ Study Setting Psychiatric Comorbidity Assessment Celiac Disease Diagnostic Criteria
Substance-related and addictive disorders
Roos (2006) [71] Sweden To assess psychological well-being in adults withCD with proven remission (treated for 10 years) Cross-sectional Clinical PGWB
Remission was ascertained with a return of
villous structure at repeat biopsy (82%) or
negative serology (18%)
Gili (2013) [72] Spain
To study the impact of alcohol disorders on
length of hospital stays, over-expenditures during
hospital stays, and excess mortality in CD
patients
Cross-sectional Clinical ICD ICD
Neurocognitive Disorders
Lebwohl (2016) [73] Sweden To determine whether patients with CD have anincreased risk of dementia
Population-based
cohort Community ICD Biopsy
Various psychiatric conditions
Fera (2003) [74] Italy To estimate the incidence of psychiatric disordersin celiac disease patients on gluten withdrawal Cross-sectional Clinical DSM-IV criteria Biopsy & Clinical history
Sainsbury (2013) [75] Australia
To compare the relevant impact of psychological
symptoms to known negative impacts of
gastrointestinal symptoms and adherence to the
GFD on quality of life
Study 1:
Cross-sectional
Study 2:
Cross-sectional
Clinical
DASS
EDI-3
CISS
Biopsy
Zylberberg (2017) [76] US
To assess the prevalence of depression and
insomnia among patients with CD, both
diagnosed and undiagnosed, and people without
CD who avoid gluten
Population-based
cross-sectional Community
PHQ-9 (Total score on questions 1–9 ≥ 10)
SDQ
Diagnosed CD: self-reported diagnosis
Undiagnosed CD: serology
* Included patients of all age groups (pediatrics and adults); ‡ The design was determined by the authors of the current review which might not coincide with the design described in the
original studies; for studies including multiple methodologies, the design that achieved the objectives of interest was selected; ADHD: Attention-deficit/hyperactivity disorder; BES: Binge
Eating Scale; CD: celiac disease; CDS: Children Depression Scale; CIDI-DSM-IV: Composite International Diagnostic Interview for DSM-IV; CISS: Coping Inventory for Stressful Situations;
DASS: Depression Anxiety Stress Scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; EAT: Eating Attitudes Test; EDI: Eating Disorder Inventory; EDRS: Eating Disorder
Risk Scale; EPDS: Edinburgh Postnatal Depression Scale; GFD: gluten-free diet; HADS: Hospital Anxiety and Depression Scale; IBD: inflammatory bowel disease; ICD: International
Classification of Disease; IDSQ: Ipat Depression Scale Questionnaire; LSAS: Liebowitz Social Anxiety Scale; MMPI: Minnesota Multiphasic Personality Inventory; M-SDS: Modified Zung
Self-Rating Depression Scale; NA: not applicable; NCGS: non-celiac gluten sensitivity; NA: not applicable; NR: not reported; PGWB: Psychological General Well-being; PHQ: Patient
Health Questionnaire; PPD: post-partum depression; PSS: Perceived Stress Scale; SCL: Symptom Check List; SDQ: Sleep Disorder Questionnaire; SRDS: Zung Self-Rating Depression Scale;
STAI: State and Trait Anxiety Inventory; STAI: State and Trait Anxiety; STPI: Spielberger State Trait Personality Inventory.
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A summary of results of studies evaluating the association between CD and the occurrence or
presence of psychiatric disorders is presented in Table 4.
The prevalence rates of depression or depressive symptomatology were significantly higher
in patients with CD compared to controls in the majority of the published studies except for
two [56,60]. Nevertheless, significant variability in the point-prevalence of depression or depressive
symptomatology exists, ranging from 14% to 68.7% [53,56,57,59,60,63]. In a meta-analysis conducted
by Smith et al. [61], depression was shown to be more common and severe in CD than in healthy
adults, but not compared to patients with other medical conditions. Comorbid illnesses, including
type I diabetes mellitus or subclinical thyroid disease, and stress were associated with the presence
of depressive symptomatology in CD [57,60]. Increased severity of gastrointestinal symptoms in
CD was linked to worsened depressive symptoms [75] which, in turn, led to poorer QOL compared
to controls [63]. Although gluten-free diet (GFD) did not lead to any improvement in depressive
symptoms in two longitudinal studies [52,55], a meta-analysis conducted by Sainsbury et al. [66]
found a moderate association between poor adherence to GFD and greater depressive symptoms.
With respect to post-partum depression, it was assessed in a single study in which it turned out to be
significantly more prevalent in women with CD compared to controls (41% vs. 11%, p < 0.01) [65].
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Table 4. Summary of outcomes evaluating the association between gluten-related disorders and psychiatric disorders in adults.
Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and other Relevant Information
Attention-Deficit/Hyperactivity Disorder
Zelnik (2004) [45] Cross-sectional CD, n = 111 (mean age 20.1 years, 57.7% females)Controls, n = 211 (mean age 20.1 years, 59.7% females)
- ADHD diagnosis:
20.7% in CD vs. 10.5% in controls (p <0.01)
CD, 20.3% of female patients and 21.2% of male patients
Controls, 8.7% of females and 12.9% males
-No gender differences were found in the
prevalence of ADHD in patients with CD
-Differences in ADHD were not different among
CD patients presenting with infantile form of CD
or late-onset symptoms
Autism spectrum disorders
Ludvigsson (2013)
[46] Cohort study
Group 1, n = 26,995 (age at diagnosis, 0–19 years 40.4%, >20
years 59.6%; 62.1% females); Controls, n = 134,076 (matched
age and gender)
Group 2, n = 12,304 (age at diagnosis, 0–19 years 8.9%, >20
years 91.1%; 56.9% females); Controls, n = 60,654 (matched
age and gender)
Group 3, n = 3719 (age at diagnosis, 0–19 years 25.3%, >20
years 74.7%; 62.1% females; 62.1% females); Controls, n =
18,478 (matched age and gender)
- Risk of later ASD diagnosis:
Group 1: HR = 1.39 (95% CI: 1.13–1.71)
Group 2: HR =2.01 (95% CI: 1.29–3.13)
Group 3: HR = 3.09 (95% CI: 1.99–4.8)
NR
Schizophrenia Spectrum
West (2006) [47] Population-basedcase-control
CD, n = 4732; matched controls, n = 23,620
Crohn’s disease, n = 5961; matched controls, n = 29,843
Ulcerative colitis, n = 8301; matched controls, n = 41,589
Demographics NR
- Prevalence of schizophrenia
0.25% in CD, 0.27% in Crohn’s disease and 0.24% in ulcerative
colitis, 0.37% in general population
- ORs for schizophrenia compared to controls adjusted for
smoking status:
0.76 (95% CI: 0.4-1.4) in CD, 0.74 (95% CI: 0.4–1.3) in Crohn’s
disease, 0.71 (95% CI 0.4–1.1) in ulcerative colitis
NR
Eaton (2006) [48] Cross-sectional Schizophrenia, n = 7704, 25 controls for each case.Demographics NR
- Prior CD diagnosis in subjects with schizophrenia:
Crude incidence rate: 3.8 (95% CI: 1.3–11)
Adjusted incidence rate: 3.6 (95% CI: 1.2–10.6)
NR
Benros (2011) [49] Population-basedcohort
Schizophrenia, n = 39,076:
Prior diagnosis of autoimmune disease, n = 927,
autoimmune disease and infections, n = 444, without
autoimmune disease, n = 37,705
Demographics NR
- The risk of schizophrenia among individuals with CD was
increased:
CD without infection: Incidence rate ratio = 2.11 (95% CI: 1.09–3.61)
CD with infections: Incidence rate ratio = 2.47 (95% CI: 1.13–4.61)
NR
Wijarnpreecha
(2018) [50] Meta-analysis Four studies were included
- Higher risk of schizophrenia among patients with CD was found;
pooled OR = 2.03 (95% CI: 1.45–2.86) NR
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Table 4. Cont.
Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and other Relevant Information
Bipolar, depressive and anxiety disorders
Hallert (1982) [51]
Hallert (1983) [52]
Phase 1:
cross-sectional
Phase 2: case-series
CD, n = 12 (mean age 47 years, 67% females)
Controls undergoing cholecystectomy, n = 12 (mean age 47
years, 67% females)
- MMPI depression subscale:
Significantly higher scores in CD vs. controls (70.3 ± 12.5 vs.
59.2 ± 9.3, p <0.01)
- MMPI sores:
Post-remission in small intestinal mucosa following GFD in CD: no
improvement in mood (70 ± 12.5 at point 0 vs. 68 ± 14 at year 1,
p = NS)
- Post-cholecystectomy in controls: No change in MMPI scores
- Supplementation with Vitamin B6 80 mg/day for 6 months:
Significant decrease in depressive symptoms (68 ± 14.0 to 56 ± 8.5,
p <0.01)
-In patients with CD, significant correlation was
found between depression scores and degree of
steatorrhea
-No correlation was found between abdominal
complaints (diarrhea and pain) and depression
scores
Addolorato (1996)
[53] Case-control
CD, n = 20 (mean age 37 years, 56% females)
IBD, n = 16 (mean age 32 years, 56% females)
Controls, n = 16 (mean age 35 years, 56% females)
- Prevalence of State anxiety:
62.5% in CD, 50% in IBD, and 31.3% in controls (p = NS).
- Prevalence of depression:
68.7% in CD, 37.5% in IBD, and 18.8% in controls (p <0.01 for CD vs.
controls only)
NR
Ciacci (1998) [54] Cross-sectional
CD, n = 92 (mean age 29.4 years, 70% females)
CPH, n = 48 (mean age 31.8 years, 34% females)
Controls, n =100 (mean age 30 years, 71% females)
- Mean scores of the M-SDS:
CD: 31.81 ± 7.84
CPH: 28.73 ± 7.09 (p = 0.038 vs. CD)
Controls: 27.14 ± 5.26 (p <0.0001 vs. CD)
- Demographic characteristics did not influence
M-SDS scores
-Depressive symptoms are present to a similar
extent in patients with childhood- and
adulthood-diagnosed CD
Addolorato (2001)
[55]
Phase 1:
Cross-sectional
Phase 2:
Case-series
CD, n = 35 (mean age 29.8 years, 60% females)
Controls, n = 59 (mean age 31.7 years, 54% females)
Before diet:
- Prevalence of high levels of state anxiety:
CD vs. control: 71.4% versus 23.7% (p <0.0001)
- Prevalence of high levels of trait anxiety:
CD vs. controls: 25.7% versus 15.2% (p = NS)
- Prevalence of depression
CD vs. controls: 57.1% versus 9.6% (p <0.0001)
After 1 year of GFD (T0 vs. T1)
- Prevalence of high levels of state anxiety:
T0 71.4% versus T1: 25.7% (p <0.001)
- Prevalence of high levels of trait anxiety:
T0: 25.7% versus T1: 17.1% (p = NS)
- Prevalence of depression
T0: 57.1% versus T1:45.7 (p = NS)
NR
Cicarelli (2003) [56] Cross-sectional CD, n = 176 (mean age 30.9 years, 75% females)Controls, n = 52 (mean age 31.7 years, 65% females)
- Prevalence of mood disorders (CD vs. controls):
Mood disorders 50 (29%) vs. 9 (17%), p = NS
Depression episodes 24 (14%) vs. 7 (13%), p = NS
Dysthymia 26 (15%) vs. 2 (4%), p <0.05
- Adherence to a
strict gluten-free diet was associated with a
significant reduction of dysthymia
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Table 4. Cont.
Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and other Relevant Information
Bipolar, depressive and anxiety disorders
Carta (2002) [57]
Carta (2003) [58] Cross-sectional
CD, n = 36 (mean age 41.1 years, 75% females)
Controls, n = 144 (mean age 41.3 years, 75% females)
- Lifetime prevalence of psychiatric disorders (cases vs. controls):
Major depressive disorder 15 (41.7%) vs. 30 (20.8%), p = 0.01
Dysthymic disorder 3 (8.3%) vs. 2 (1.4%), p = 0.05
Adjustment disorders 11 (30.5%) vs. 11 (7.6%), p = 0.001
Generalized anxiety disorder 10 (27.7%) vs. 23 (16%), p = NS
Panic disorder 5 (13.9%) vs. 3 (2.1%), p = 0.001
Specific phobia 1 (2.7%) vs. 6 (4.2%), p = NS
Social phobia 3 (8.3%) vs. 10 (6.9%), p = NS
Recurrent brief depression 36.1% versus 6.9% (OR = 7.6; 95% CI:
3.2–17.8)
- Earlier onset of CD was linked to higher
prevalence of major depressive disorder
- Subclinical thyroid disease appears to represent a
significant risk factor for these psychiatric
disorders
Addolorato (2008)
[59] Cross-sectional
CD, n = 40 (mean age 38 years, 86% females)
HC, n = 50 (mean age 36 years, 80% females)
- Prevalence of social phobia:
70% in CD vs. 16% in HC (p <0.0001)
- Prevalence of depression:
53% in CD vs. 8% in HC (p <0.0001)
- The prevalence of social phobia or depression in
patients with CD did not differ among subjects
newly diagnosed with CD and those already on
GFD
Garud (2009) [60] Cross-sectional
CD, n = 600 (mean age 54 males & 49 females, 75% females)
IBS, n = 200 (mean age 48 males & 45 females, 75% females)
Controls, n = 200 (mean age 52 males & 47 females, 75%
females)
Prevalence of depression:
17.2% in CD vs. 18.5% in IBS (p = 0.74 vs. CD) and 16% in controls
(p = 0.79 vs. CD)
- Among CD patients, type I diabetes mellitus was
identified as a significant risk factor for depression
(p <0.01) with 37% of patients with both CD and
type I DM having clinical depression
Smith (2012) [61] Meta-analysis Eleven studies on depression and eight studies on anxietywere included
- Depression is more common and severe in CD than in healthy
adults with an overall effect size of 0.97
- Anxiety did not differ significantly between CD and healthy adults
- No differences in depression or anxiety in CD vs. other
medical disorders
- Other medical conditions included: Crohn’s
disease, DM, IBD, lactose intolerance, surgery
patients, CPH
Peters (2014) [62]
Randomized,
double-blind,
cross-over trial
NCGS, n = 22 (median age 48 years, 77% females)
- Gluten ingestion effect on STPI depression scores:
Significantly higher scores in CD vs. controls (mean difference =
2.03, 95% CI: 0.55–3.51, p = 0.01)
- No differences in other STPI state indices or for any STPI trait
measures
NR
Carta (2015) [63] Cross-sectional CD, n = 46 (mean age 41 years, 83% females)Controls, n = 240 (mean age 41 years, 83% females)
- Prevalence of depression:
30.0% in CD vs. 8.3% in controls, p <0.0001
- Prevalence of panic disorder:
18.3% in CD vs. 5.4% in controls, p <0.001
- Prevalence of bipolar disorder: 4.3% in CD vs. 0.4% in controls,
p <0.005
- Patients with CD but without comorbidity with
major depression, panic disorder, or bipolar
disorder do not show worse QOL than controls
Di Sabatino (2015)
[64]
Randomized,
double-blind,
placebo-controlled
cross-over trial
NCGS, n = 61 (mean age 39 years, 87% females) randomly
assigned to:
Gluten 4.375 mg/day for 1 week
Placebo 4.375 g/day rice starch for 1 week
Wash-out period: 1 week
- Depression was significantly worsened by gluten ingestion
(p = 0.02) NR
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Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and other Relevant Information
Bipolar, depressive and anxiety disorders
Tortora (2013) [65] Cross-sectional CD, n = 70 (mean age 33 years)Controls, n = 70 (mean age 32 years)
- EPDS scores in CD women vs. controls:
9.9 ± 5.9 vs. 6.7 ± 3.7, p <0.01
- EPDS > 10:
47% in CD vs. 14% in controls (OR = 3.3, p <0.01)
- PPD diagnosis:
41% of CD women with vs. 11% in controls (p <0.01)
- A significant association was observed between
the onset of PPD and a previous menstrual
disorder in women suffering from CD
- QOL scores were significantly higher in women
with CD
Sainsbury (2018)
[66] Meta-analysis
Eight studies were included in quantitative analysis (total n
= 1644, mean age ranged from 39 to 57 years, % of females
ranged from 76.6% to 100%)
- Moderate association between poor adherence to GFD and greater
depressive symptoms (r = 0.398, 95% CI: 0.32–0.47) with marked
heterogeneity in effects (I2 = 66.8%)
- Exclusion of studies with high or unclear risk of bias did not alter
the results
- Poorer QOL was correlated with a higher
incidence of psychological and gastrointestinal
symptoms, greater reliance on maladaptive coping
strategies, and poorer GFD adherence
Feeding and eating disorders
Passananti (2013)
[67] Cross-sectional
CD, n = 100 (mean age 29 years, 72% females)
HC, n = 100 (mean age 30 years, 68% females)
- BES ≥ 17:
6% in CD vs. 0% controls (p = NS)
- Women with CD had significantly higher scores in pulse thinness,
social insecurity, perfectionism, inadequacy, ascetisim, and
interpersonal diffidence compared to HC women of the Eating
Disorder Inventory
- EAT-26 ≥ 20:
16% in CD vs. 4% in HC (p = 0.01)
- SRDS > 44:
39% in CD vs. 6% in controls (p <0.001)
- SCL-90 pathological scores:
42% in CD vs. 6% in HC (p <0.0001)
- EAT-26 demonstrated association between
indices of diet-related disorders in both CD and
the female gender after controlling for anxiety and
depression
Satherley (2016)
[68] Cross-sectional
CD, n = 157 (mean age 38 years, sex NR)
IBD, n = 116 (mean age 36 years, sex NR)
DM-type 2, n = 88 (mean age 47 years, sex NR)
HC, n = 142 (mean age 33 years, sex NR)
- EAT-26 > 20:
15.7% in CD vs. 8.8% in DM and 3.8% in HC (p <0.05)
- BES > 17:
19.4% in CD vs. 2.3% in controls (p <0.05)
- Mean EAT-26 and BES scores:
11.1 in CD vs. 7.7 in controls (p <0.05) and 11.2 in CD vs. 3.9 in
controls (p <0.05), respectively
- Significant associations between EAT-26 and BES scores with
DASS-21 scores were reported (p <0.008)
- Dietary-management and gastrointestinal
symptoms were significantly associated with EAT
scores in CD
Mårild (2017) [69] Population-basedcohort study
Group 1, n = 17,959 (median age 28 years); Matched
controls, n = 89,379
Group 2, n = 7455 (median age 46 years); Matched controls,
n = 36,940
Group 3, n = 2307 (median age 38 years); Matched controls,
n = 11,499
- Risk of developing anorexia nervosa:
Group 1: HR= 1.46 (95% CI: 1.08–1.98)
Group 2: HR=2.12 (95% CI: 0.97–4.67)
Group 3: HR=2.45 (95% CI: 1.10–5.45)
- Adjustment for education level, socioeconomic status, and type 1
DM didn’t affect conclusions in all groups
- There was no significantly increased risk for
subsequent anorexia nervosa among males with
CD
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Sleep-Wake disorders
Mårild (2015) [70] Population-basedcohort study
CD, n = 2933 (median age 28 years, 61.2% females)
Controls, n = 14,571 (median age 28 years, 61.3 females)
- Poor sleep in CD vs. controls:
12.5% vs. 9.8% (HR = 1.36, 95% CI: 1.30–1.41)
- Individuals with CD had a similar increased
risk irrespective of age at CD diagnosis, sex and type of
hypnotic used
- Overall, poor sleep was more prevalent in
females than in males. However, differences in risk
estimates for poor sleep were small between
females and males with CD
- Adjustment for sleep apnea and restless leg
syndrome did not influence the risk of poor sleep
in CD
Substance-related and addictive disorders
Roos (2006) [71] Cross-sectional CD, n = 51 (age 45–64 years, 59% females)Controls, n = 182 (age 45–64 years, 57% females)
- PGWB index scores:
103 (95% CI: 99–107) in CD vs. 103 (95% CI: 100–106) in controls
(p = NS)
- Males with CD tended to score higher on the
PGWB domains than the male controls
- CD women scored somewhat lower in the PGWB
domains than the female controls
- CD men tended to score higher than the CD
women in all six domains of the PGWB
Gili 2013 [72] Cross-sectional
CD, n = 3327 (mean age 49 years and 70% females).
Controls, n = 5,471,988) (mean age 58 years and 54%
females).
- Prevalence of alcohol disorders:
4.9% in CD vs. 6.3% in controls (p = 0.0009)
- The presence of alcohol disorders in CD
increased the length of stay, costs and had an
excess of mortality
Neurocognitive Disorders
Lebwohl (2016)
[73]
Population-based
cohort
CD, n = 8846 (mean age 64 years and 56% females).
Control, n = 43,474 (mean age 64 years and 56% females).
- In a median follow-up period of 8.4 years:
4.3% of CD patients and 4.4% of controls had a diagnosis of
dementia (HR 1.07; 95% CI 0.95–1.20)
- A subgroup analysis showed an increased risk of vascular
dementia (HR 1.28; 95% CI 1.00–1.64)
- A significant association between CD and
dementia among the age group 60–69 was found,
which was not present in the younger or older age
groups
- Increased risk of dementia was found in the first
year following CD diagnosis
Various psychiatric conditions
Fera (2003) [74] Cross-sectional
CD, n = 100 (mean age 40 years, 75% females)
DM, n = 100 (mean age 53 years, 74% females)
HC, n = 100 (mean age 41 years, 68% females)
- CD, prevalence of OCD 28%, depressive disorder/dysthymia 19%
- DM, prevalence of OCD 0%, depressive disorder/dysthymia 10%
HC, anxiety and depression in 10% of subjects
- QOL was poorer in both CD and diabetic patients
than in healthy controls and significantly
correlated with anxiety
Sainsbury (2013)
[75]
Study 1:
cross-sectional n = 390 (mean age 44 years, 82.8% females)
- Severe gastrointestinal symptoms at CD diagnosis were
associated with:
increased depression (r = 0.28, p <0.001), anxiety (r = 0.29, p <0.001),
stress (r = 0.28, p <0.001), eating disorder (r = 0.15, p <0.01), and
emotion-oriented coping (r = 0.17, p <0.01)
- Poorer QOL was significantly associated with a
greater number and longer duration of CD
symptoms prior to diagnosis
- Higher number of symptoms was associated with
poorer QOL
- There were no gender differences in QOL,
although females reported a greater number of
symptoms
- More severe gastrointestinal symptoms at
diagnosis were also associated with increased
psychological manifestations
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Table 4. Cont.
Various psychiatric conditions
Author (Year) Design Sample Size and Demographic Characteristics Summary of Outcomes Associated Factors with PsychiatricComorbidities and other Relevant Information
Sainsbury (2013)
[75]
Study 2:
cross-sectional n = 189 (mean age 46.5 years, 87.3% females)
- Hierarchical regression analyses:
Current psychological distress significantly contributed to poor
QOL (accounting for 23.8% of the variance in QOL)
Zylberberg (2017)
[76]
Population-based
cross-sectional
Diagnosed CD, n = 27 (age NR, 78% females)
Undiagnosed CD, n = 79 (age NR, 58% females)
PWAG; n = 213 (age NR, 55% females)
Controls; n = 14,769 (demographic characteristics NR)
- Prevalence of depression:
8.2% of controls vs. 3.9% in CD (p = 0.18) and 2.9% in PWAGs
(0.002)
- Prevalence of sleep difficulty:
37.3% in CD, 34.1% in PWAGs vs. 27.4% in controls (p = NS)
- Multivariate analysis adjusted for race/ethnicity, annual
household income, number of healthcare visits:
PWAGS, significantly lower odds of depression (OR = 0.25, 95% CI:
0.12–0.5, p = 0.0001)
CD, OR = 0.30; 95% CI: 0.08–1.19, p = 0.09
- QOL: The presence of physical, mental, and
emotional limitations was reported in 2.9% of
controls vs. 13.8% diagnosed CD (p =0.004), 9.6%
with undiagnosed CD (p = 0.02), and 5.1% in
PWAGs (p = 0.18)
ADHD: Attention-Deficit Hyperactivity Disorder; ASD: Autistic Spectrum Disorders; BES: Binge Eating Scale; CD: celiac disease; CI: confidence interval; CPH: Chronic persistent hepatitis;
DASS: Depression Anxiety Stress Scale; DM: Diabetes Mellitus; EAT: Eating Attitudes Test; EPDS: Edinburgh Postnatal Depression Scale; GFD: gluten-free diet; HC: healthy controls; HR:
hazard ratio; IBD: Inflammatory Bowel Disease; IBS: Irritable Bowel Syndrome; MMPI: Minnesota Multiphasic Personality Inventory; M-SDS: Modified Zung Self-Rating Depression Scale;
NCGS: non-celiac gluten sensitivity; NR: not reported; NS: not significant; OCD: Obsessive-Compulsive Disorder; OR: odd ratio; PGWB: Psychological General Well-being; PWAG: people
who avoid gluten; QOL: quality of life; QOL: quality of life; RR: relative risk; SCL: Symptom Check List; SRDS: Zung Self-Rating Depression Scale; vs: versus.
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In two studies conducted by the same research group, the prevalence of state anxiety in patients
with CD was substantially higher than in controls (62.5% vs. 31.3%, and 71.4% vs. 23.7%), although the
difference was statistically significant in only one study [53,55]. Generalized anxiety disorder diagnosis
in CD was not shown to be prevalent in CD compared to controls [57] and the overall prevalence of
anxiety was not significantly higher compared to healthy adults in the meta-analysis conducted by
Smith et al. [61]. The prevalence of social phobia in CD reached 70% in one cross-sectional study [59];
however, its lifetime prevalence in another study was only 8.3% [57]. Bipolar disorder and panic
disorders were significantly more prevalent in patients with CD [57,58,63].
Three studies assessed the prevalence and risk of eating disorders in CD. Their prevalence
was significantly higher in adults with CD compared to healthy controls as demonstrated via the
elevated scores on the different assessment scales employed in two cross-sectional studies [67,68].
Elevated Eating Attitudes Test scores were seen in around 16% of patients with CD in both studies,
whereas elevated Binge Eating Scale scores were only elevated in one study with 19.7% of adults
with CD reporting high scores [68]. Moreover, severe gastrointestinal symptoms were linked to
greater risk of eating disorders [75]. In the register-based cohort and case-control study conducted by
Marild et al. [69], the likelihood of developing anorexia nervosa was significantly higher in women
with CD (HR = 1.46, 95% CI: 1.08–1.98) and the likelihood was highest in women with normal mucosa
and positive serology (HR = 2.45, 95% CI: 1.1–5.45).
While patients with CD were less likely to experience alcohol-related disorders [72], their risk of
developing dementia was significantly higher as shown in a population-based cohort study [70,73].
The likelihood of developing poor sleep in CD based on the use of hypnotics was significantly
elevated compared to controls HR = 1.36, 95% CI: 1.3–1.41) in the population-based case-control study
conducted by Marild et al. [70]. On the other hand, sleep difficulty as measured with the Patient Health
Questionnaire did not differ significantly between adults with CD and controls (37.3% vs. 27.4%,
p = 0.15) in a population-based cross-sectional study [76].
While gender did not seem to affect the prevalence rates of ADHD in CD patients [45], males with
CD were less likely to experience poor sleep problems [70] or subsequent anorexia nervosa [69] and
they tended to score higher on the different Psychological General Well-being Index domains [71].
Conflicting results concerning the effect of the CD onset time on psychological symptomatology
were obtained; on one hand, earlier onset of CD symptoms was linked to higher prevalence of major
depressive disorder in one study [57] and on the other hand, depressive symptomatology scores did
not differentiate between childhood or adulthood diagnosis of CD [54]. Finally, severe gastrointestinal
symptomatology significantly correlated with increased psychological manifestations [68,75].
The risk of schizophrenia in patients with CD was assessed in three studies [47–49]. While one
population-based case-control study showed no increased risk of schizophrenia in CD (OR = 0.75,
95% CI: 0.4–1.4) [47], its risk was shown to be significantly elevated in a population-based cohort
study (Incidence rate ratio = 2.11, 95% CI: 1.1–3.6) and a cross-sectional study (adjusted incidence
rate = 3.6, 95% CI: 1.2–10.6) [48,49]. In a meta-analysis including four studies, an increased risk of
schizophrenia among patients with CD was found (OR = 2.03, 95% CI: 1.45–2.86) [50]. With respect
to autistic spectrum disorders, its risk in a population-based cohort of CD appeared to be increased
with the highest risk being present in patients with normal mucosa and positive serologic findings
(HR = 3.09, 95% CI: 1.99–4.8) [46].
ADHD was assessed in one cross-sectional study that reported an increased prevalence of this
disorder in adults with CD compared to controls (20.7% vs. 10.5%, p <0.01) [45]. The overall
psychological status in adults with CD was evaluated in one study whereby no difference in the
total Psychological General Well-Being Index was found between CD and controls [71].
In the two studies that evaluated the effects of gluten ingestion in adults with NCGS [62,64],
significant worsening of depressive symptomatology [64] and increase in the depression subscale
scores of Spielberger State Trait Personality Inventory [62] were reported.
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4. Discussion
Our current review of the literature revealed the existence of an association between CD
and other gluten-related disorders with psychiatric disorders across different age groups. CD is
primarily an autoimmune disorder that is characterized by villous atrophy of the intestinal mucosa
along with intraepithelial lymphocytosis and crypt hyperplasia [77]. Nevertheless, a major shift
in clinical presentation with extraintestinal manifestations becoming more prevalent than classical
gastrointestinal symptoms has been suggested [78]. The reviewed data demonstrate that a wide
range of psychiatric disorders have been investigated in CD and NCGS including autism spectrum
disorders, schizophrenia, attention-deficit disorder, depression and mood disorders, anxiety disorders,
bipolar disorder, feeding and eating disorders, sleep disorders, substance-related and addictive
disorders and neurocognitive disorders.
Most of the cross-sectional studies in the pediatric population did not find any significant
differences in the point prevalence of depression or anxiety disorders [32,33,35–37], however,
these studies had several methodological limitations which mainly included small sample size
(ranging between 29 and 42 children with CD), the lack of specialized psychiatric clinical assessment,
and the absence of adequate blinding measures to limit assessment bias. On the other hand,
two population-based cohort studies including >9000 children each provided evidence for an increased
likelihood of occurrence of depression and anxiety disorders in patients with CD [34,44]. In the cohort
study conducted by Ludvigsson et al. [34], it was shown that adults and children with CD are at
increased risk of being diagnosed with depression but not bipolar disorder later in life (i.e., during
adulthood for children diagnosed with CD), whereas in the study conducted by Butwicka et al. [44],
CD was identified as a risk factor for mood disorders, anxiety disorders, eating disorders, behavioral
disorders, ADHD, ASD, and intellectual disability diagnosed prior to 18 years of age. Although the
analyses in the two previous cohort studies were controlled for children’s age, stratified analyses
to identify the likelihood of occurrence of specific psychiatric disorders across the different age
groups are worth evaluation taking into consideration the variation in clinical presentation across the
developmental span between 0 and 15 years of age [79].
In adults, the point-prevalence of depression was significantly higher in patients with CD in
the majority of published studies. These findings were ascertained by a population-based cohort
study in which the HR of depression (in participants ≥16 years at diagnosis) was two folds higher
than controls [34] and by a meta-analysis in which depression was shown to be more common
and severe in CD than in healthy adults with an overall effect size of 0.97 [61]. A comprehensive
review, evaluating the comorbidity of depression and anxiety in CD, concluded that these disorders are
common disorders among patients with CD and contribute to a poorer quality of life [24]. Nevertheless,
the lack of differences in the prevalence of depression when compared to patients with other physical
disorders [61] raises a question about the existence of a specific underlying pathophysiological
mechanism in patients with CD or whether depression represents a non-specific disorder affected by
physical and psychosocial distress. The association between chronic medical diseases and depression
is well-known and many different causes, including both genetic predisposition and environmental
factors have been shown to be involved [80–82]. This association is frequently bidirectional, as the
presence of physical illness often worsens the affective disorder and vice versa [81]. The current
information relative to depression in patients with CD does not allow, at the present time, to
ascertain the exact relationship and the predisposing factors involved between CD or NCGS and
depressive symptomatology.
The association between CD and eating disorders has been investigated in a limited number of
studies. Current findings reveal an elevated prevalence of eating disorders in CD among both children
and adults with CD [39,40,44,67–69]. These disorders encompassed anorexia nervosa, bulimia nervosa
and binge eating. Poor dietary management can occur as a result of physical dissatisfaction, which is
not uncommon in patients with CD [83]. Moreover, evidence from the current literature suggests that
young adults with chronic illnesses that require dietary modification are at higher risk of developing
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pathological eating practices [39]. The elevated lifetime comorbidity between depression and eating
disorders [84] could be another explanatory mechanism of increased prevalence of eating disorders in
CD patients who are more prone to developing depressive symptomatology.
Concerning psychotic disorders, the current evidence provided by solely two population-based
cohort studies does not support the presence of an association between these disorders and CD in
children [31,44]. However, children and young adults (≥16 years of age) with CD were 1.8-fold more
likely to experience non-schizophrenic non-affective psychosis [31]. The authors of the latter cohort
study yet did not rule out the presence of a potential association between CD and schizophrenia as
the risk of the latter disorder was high despite the low number of individuals with schizophrenia.
These findings were similar to another population-based case-control study conducted in adults
in which no evidence of an increased risk of schizophrenia in CD was found [47]. In contrast,
Benros et al. [49] demonstrated an increased incidence of schizophrenia in patients with prior CD
in their population-based cohort study. Furthermore, Eaton et al. [48] showed also 3.8-fold increase
in incidence rates of prior CD diagnosis in subjects with schizophrenia. However, in the latter study,
data on parents’ celiac status were also included in their analysis which might have led to biased
findings. A meta-analysis including four studies demonstrated the presence of an increased risk of
schizophrenia among patients with CD [50]. We believe that the pooled-effect estimate in the previous
meta-analysis could be biased because their pooled analysis on one hand missed the negative findings
reported by West et al. [47] and on the other hand included the findings of a study in which the
prevalence of CD in patients with schizophrenia was investigated [85]. The objectives and outcome
measures of the latter study [85] did not match the principal objective of the meta-analysis whereby
the authors investigated the prevalence of autoimmune diseases (including CD) in patients with
schizophrenia and not the other way around [85]. The association between CD and gluten-related
disorders with schizophrenia has been under investigation for more than five decades but most
studies evaluated the prevalence or risk of gluten-related disorders in patients already diagnosed
with schizophrenia [86]. Current evidence suggests a two-fold increase in the prevalence of CD
in schizophrenia patients [87] and an association between gluten ingestion and exacerbation of
schizophrenia symptoms [88]; nonetheless, these findings are highly inconsistent across different
clinical, immunological, and epidemiological studies [86] and have not been replicated in patients
presenting with CD.
The underlying mechanisms behind the association between CD and psychiatric disorders are
not well-known. Nevertheless, several potential biological and psychosocial explanations have
been suggested: (i) Several psychiatric disorders such as depression, anxiety, and ADHD, among
others have been linked to certain nutritional and vitamin deficiencies [89] and it is well-known
that patients with CD often suffer from malnutrition prior to diagnosis or as a result of dietary
non-compliance [90]; (ii) The immune-mediated processes underlying CD have been postulated as
potential causative factors of the different psychiatric manifestations taking into consideration the
involvement of chronic immune system activation in the etiology of various psychiatric conditions [91];
(iii) The bidirectional communication between the gastrointestinal tract [92] and the brain may suggest
that alterations in the intestinal permeability, which is cardinal manifestation in CD [93], could be
eventually involved in the pathophysiology of psychiatric manifestations in patients with CD; (iv)
Finally, psychosocial aspects commonly seen in CD could place this population at an increased risk
of developing psychiatric disorders, for instance, the introduction of GFD is associated with radical
changes in daily life activities, eating habits and lifestyle which could be particularly stressful and
difficult to accept [43,94]. In addition, effective adherence to GFD entails greater burden manifested
via increased daily expenditure on more expensive products, social isolation and constant fear about
dietary mistakes [95].
The studies included in this review provided limited data on potential factors associated
with psychiatric comorbidity in patients with CD. Bearing in mind this limitation, none of the
demographic factors has been consistently associated with the presence or occurrence of psychiatric
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comorbidities and the role of ethnicity in this context has not been studied. Regarding clinical factors,
only severity of CD symptoms appears to be associated with the presence and/or severity of psychiatric
disorders [33,51,52,68,75]. In this regard, the significant positive association between increased severity
of gastrointestinal symptoms and worsening of psychiatric manifestations [75] and QOL [63] in
CD indirectly demonstrates the importance of adherence to GFD. Nevertheless, few studies have
documented the beneficial effects of GFD on psychiatric manifestations in patients with CD [27,66],
with the majority of these studies suffering from several methodological flaws limiting our capacity of
reaching definitive conclusions supporting the role of GFD in this context.
Only two studies in patients with NCGS supported the association between this relatively
new entity and depressive symptomology [62,64]. It has not been until recently that standardized
diagnostic criteria for NCGS were established [19], which might explain the limited number of studies
investigating psychiatric comorbidities in NCGS. In our current review search, we could not find any
study that investigated psychiatric comorbidities in patients with WA.
Limitations of our current review are essentially derived from the limited quality of the majority
of the studies that have investigated psychiatric disorders in CD. Most of these studies are of
cross-sectional design which does not allow establishing causal relationships and are of small sample
size, whereas very few population-based studies have been published.
Evaluating psychiatric comorbidities in different age groups adds strength to our current review
since up to the current date, none of the previous reviews had evaluated the evidence of psychiatric
disorders in children and adults with CD separately. Interestingly, according to our review, the presence
of CD in childhood seems to be associated with an increased risk of developing psychiatric disorders
later during adulthood, but not with an increased prevalence of these disorders during childhood.
5. Conclusions
Our current comprehensive review ascertains the presence of an association between CD and
psychiatric disorders with varying grades of evidence from one condition to another. In our view,
there is enough evidence supporting an association of CD with depression and, to a lesser extent,
with eating disorders. Some studies also point out to an association between CD and panic disorder,
autism and ADHD, but the evidence is limited, and these potential associations should be further
investigated. Finally, the data regarding the association of CD with schizophrenia or other anxiety
disorders is conflicting. Overall, psychiatric symptomatology which could be perceived as part of
the atypical manifestations of this chronic condition are linked to significant distortion in quality of
life and moderately increased risk of suicide [96] and thus warrants further attention. Therefore,
gastroenterologists and other healthcare professionals involved in the management of patients
with CD should be aware of the increased risk of psychiatric disorders in these patients. Thus,
routine surveillance of potential psychiatric manifestations, especially anxiety and/or depressive
symptomatology that seem to be the most common forms of disturbances, should be carried out by
the attending physician in order to refer the patient to the mental health services if necessary.
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